Liestal, Switzerland, April 25, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces Jodi Wolff, PhD, to represent Santhera as a founding member of the United Mitochondrial Disease Foundation (UMDF) Industry Advisory Council (IAC) with immediate effect.
Jodi Wolff, PhD, Director of Patient Advocacy and Medical Science Liaison at Santhera Pharmaceuticals (USA), Inc., has been nominated by the UMDF to represent Santhera as a member of the IAC based on her industry expertise and advocacy work for patients with mitochondrial disease. As a member of the IAC, Jodi Wolff becomes part of a broad stakeholder community that enables value-added industry collaboration and helps drive key UMDF initiatives.
"The UMDF Industry Advisory Council (IAC) has been created to provide a platform from which a diverse group of stakeholders can provide input for addressing key priorities within the three pillars of the Mitochondrial Disease Roadmap consisting of: diagnosis, therapeutic development and patient care," said Charles A. Mohan Jr., CEO/Executive Director of UMDF. "We are excited to have Santhera participate. Their valuable insight and advice will help guide us in developing faster non-invasive diagnostics and potential therapies for mitochondrial patients as well as develop a model for enhanced patient care. We look forward to the continuation of our productive and mutually beneficial working relationship."
Upon receiving the invitation from the UMDF to represent Santhera as a member of the IAC, Jodi Wolff, PhD, commented: "I am thrilled to be a part of the UMDF Industry Advisory Council and to continue Santhera's leadership in the field of mitochondrial disease. We value our partnership with the UMDF and I look forward to utilizing my experience to benefit families living with mitochondrial disorders."
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication for Raxone, Santhera has filed a Marketing Authorization Application (MAA) in the European Union and Switzerland. In collaboration with the US National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone in a third indication, primary progressive multiple sclerosis (PPMS), and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet medical need. For further information, please visit the Company's website www.santhera.com.
Raxone® is a trademark of Santhera Pharmaceuticals.
About UMDF
Founded in 1996, the United Mitochondrial Disease Foundation (UMDF) works to promote research and education for the diagnosis, treatment and cure of mitochondrial diseases and to provide support for affected individuals and families. Since its inception, the UMDF has funded nearly USD 11 million in research, making it the leading non-governmental contributor of grants focused solely on mitochondrial disease. The UMDF, based in Pittsburgh, PA, is a US-national organization, represented around the world by thousands of members. For more information about mitochondrial disease or the UMDF, visit www.umdf.org.
For further information, contact:
Thomas Meier, PhD, Chief Executive Officer Christoph Rentsch, Chief Financial Officer
Phone +41 61 906 89 64 Phone +41 61 906 89 65
thomas.meier@santhera.com christoph.rentsch@santhera.com
Sue Schneidhorst, Head Group Communications
Phone +41 61 906 89 64
sue.schneidhorst@santhera.com
US investor contact US Public Relations contact
Hans Vitzthum, LifeSci Advisors, LLC John Gillespie, Medical Dynamics
Phone +1 212 915 2568 Phone +1 646 599 8626
hans@lifesciadvisors.com jgillespie@rxmedyn.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
